Summary
This study was designed to evaluate the clinical tolerance to multiple IM injections of rDNA-produced human alpha-2 interferon (IFN) (Schering-Plough 30500) in patients with solid tumours. IFN was administered in escalating IM doses in separate groups of patients daily for 14 days and then twice weekly for a further 10 weeks. The dosage levels were 1, 3, 10, and 30 million Ulinjection. Subjective toxicity could be divided into two types, acute and chronic. The acute reactions took the form of an influenza-like syndrome consisting in chills, rigors, headache, tremor, nausea, vomiting, and myalgia. These symptoms were dose-related but tachyphylaxis developed with continued dosing. The chronic toxicity consisted of malaise, lethargy, fatigue, anorexia, and confusion. These symptoms were not so dose-dependent and tended to become more severe with prolonged treatment. Objective toxicity consisted of myelosuppression and liver dysfunction. Granulocyte counts below 1.0x109/l were seen in three patients at the 30-million-U level, with platelet counts less than 100 x 109/l in two of these. Elevation of the liver enzymes were seen in all five patients treated at 30 million U, but returned to normal after 1 week without IFN in all but one patient. A tolerable dose (IM) for phase II/III studies lies between 3 and 10 million U for daily scheduling and between 10 and 30 million U for twice-weekly injections.
Similar content being viewed by others
References
Edelstein MB, Schellekens H, Laurent T, Gauci L (1983) A phase I clinical tolerance study of rDNA alpha 2 human interferon in patients with non-reticuloendothelial system malignancies. Eur J Cancer Clin Oncol 19:891–894
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214
Nagata S, Taira H, Hall A et al. (1980) Synthesis in E. coli of a polypeptide with human leucocyte interferon activity. Nature 284:316–320
Priestman TJ (1980) Initial evaluation of human lymphoblastoid interferon in patients with advanced malignant disease. Lancet II:113–118
Sherwin SA, Knost JA, Fein S, Abrams PG et al (1982) A multiple-dose phase-I trial of recombinant leukocyte A interferon in cancer patients. JAMA 248:2461–2466
Smedley HM, Wheeler T (1983) Toxicity of interferon: In: Sikora K (ed) Interferon and cancer. Plenum, New York, pp 203–210
Streuli M, Nagata S, Weissmann C (1980). At least three human alpha interferons: structure of alpha 2. Science 209:1343–1347
Tank B, Marquet RL, Weimar W, Aestbroek DL (1983) Therapy with high-dose recombinant alpha 2 interferon produces a depression in natural killer cell cytotoxicity. Br J Cancer
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wagstaff, J., Chadwick, G., Howell, A. et al. A phase I toxicity study of human rDNA interferon in patients with solid tumours. Cancer Chemother. Pharmacol. 13, 100–105 (1984). https://doi.org/10.1007/BF00257123
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00257123